Discovery and Development of Antiangiogenetic Drugs in Ovarian Cancer

Maile, Madon M.; Wong, Evelyn; Suzin, Daphne; Birrer, Nicole

doi:10.2174/9781608058662114020008

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The associated side effects of sunitinib are related to pulmonary toxicity, causing dyspnea and cough [110]. Pazopanib is a second-generation, small molecule multiple tyrosine kinase inhibitor that targets VEGF, PDGF, FGFR, stem cell factor receptor, colony-stimulating factor 1 receptor, and lymphocyte-specific protein tyrosine kinase receptor [14,111,[113][114][115]. Pazopanib has been used in the treatment of renal cancer, epithelial ovarian cancer, and soft tissue sarcoma, but its administration has been associated with potential cardiovascular toxicities, namely high blood pressure and abnormal ventricular repolarization [115].…”

Section: Conventional Anti-angiogenic Drugs and Their Limitationsmentioning

confidence: 99%

Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment

Teleanu

Chircov

Grumezescu

et al. 2019

JCM

348

251

View full text Add to dashboard Cite

Angiogenesis is the process through which novel blood vessels are formed from pre-existing ones and it is involved in both physiological and pathological processes of the body. Furthermore, tumor angiogenesis is a crucial factor associated with tumor growth, progression, and metastasis. In this manner, there has been a great interest in the development of anti-angiogenesis strategies that could inhibit tumor vascularization. Conventional approaches comprise the administration of anti-angiogenic drugs that target and block the activity of proangiogenic factors. However, as their efficacy is still a matter of debate, novel strategies have been focusing on combining anti-angiogenic agents with chemotherapy or immunotherapy. Moreover, nanotechnology has also been investigated for the potential of nanomaterials to target and release anti-angiogenic drugs at specific sites. The aim of this paper is to review the mechanisms involved in angiogenesis and tumor vascularization and provide an overview of the recent trends in anti-angiogenic strategies for cancer therapy.

show abstract